CION Ameerpet
Most brain tumours are given a WHO grade (1–4), not a stage like other cancers. Here is what your grade really means — explained clearly by CION's neuro-oncology team.
If you have just been handed a report and you are searching for "what stage is my brain tumour?", here is the honest, reassuring answer: most brain tumours do not have a stage at all. They have a grade.
The stage system you may have heard about — Stage 1, 2, 3, 4 — was built for cancers that spread through the body, such as breast or lung cancer. It measures how far a cancer has travelled. Primary brain tumours behave differently: they grow and invade inside the brain but almost never spread to other organs. So instead of a stage, doctors give them a WHO grade from 1 to 4 — a measure of how aggressive the tumour cells look. Your grade, along with molecular markers, is what actually drives your treatment plan.
The World Health Organization (WHO) classifies primary brain and central nervous system tumours by grade (1–4), not by the TNM stage used for most other cancers. The current framework — the WHO Classification of Tumours of the Central Nervous System (5th edition, 2021) — combines how the cells look under the microscope with molecular markers such as IDH mutation. National guidelines from the NCCN and the European Association of Neuro-Oncology (EANO) use this grade, not a stage, to plan treatment.
These two words are easy to mix up, but they answer completely different questions. Understanding the difference takes a lot of the fear out of a new report.
A stage maps the spread of a cancer: the size of the original tumour, whether nearby lymph nodes are involved, and whether it has reached distant organs. This is the familiar TNM system (Stage 1 to Stage 4). It works well for cancers that travel through the body — but not for tumours that stay put inside the brain.
A grade is decided by a pathologist examining the tumour tissue and its molecular markers. It describes how abnormal and fast-growing the cells look — from slow Grade 1 to aggressive Grade 4. For brain tumours, the grade is the number that matters most, because it predicts how quickly the tumour is likely to grow and how urgently it needs treatment.
In one line: stage answers where a cancer is; grade answers how it behaves. Brain tumours are described by grade because they rarely go anywhere else.
The World Health Organization grades brain tumours from Grade 1 to Grade 4. Higher is more aggressive — but higher does not mean hopeless. Here is what each grade broadly means. For a fuller breakdown, see our dedicated guide to WHO brain tumour grades (1–4) explained.
| WHO Grade | How It Behaves | Common Examples |
|---|---|---|
| Grade 1 | Very slow-growing; often controllable, and sometimes curable with surgery alone | Pilocytic astrocytoma, many meningiomas |
| Grade 2 | Slow-growing but can progress over years; watched closely | Diffuse astrocytoma, oligodendroglioma |
| Grade 3 | Moderately aggressive; usually needs combined treatment | Anaplastic astrocytoma |
| Grade 4 | Fast-growing and most aggressive; intensive treatment | Glioblastoma (GBM) |
Since the 2021 WHO update, grade is set using both how the cells look and molecular markers — so the grade on your report already reflects modern testing where it has been done.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Bring your MRI report or biopsy result. CION's tumour board reviews your exact grade and molecular markers — then explains what they mean for you.
Staging systems were designed to track cancers that spread — from the original organ, to nearby lymph nodes, to distant sites. That journey is exactly what a stage measures. Primary brain tumours do not usually make that journey.
The brain sits behind the blood–brain barrier and has no lymph node system like the rest of the body. So even an aggressive tumour tends to grow and invade within the brain rather than travelling to the lungs, liver or bones. Because there is no distant spread to map, a TNM stage would tell doctors very little.
What does matter is how fast the tumour is likely to grow and how deeply it invades nearby brain tissue — and that is precisely what the WHO grade captures. This is why neuro-oncology guidelines from the NCCN and EANO plan treatment around grade and molecular markers, not stage.
An MRI can strongly suggest a brain tumour, but the grade is confirmed on tissue. Here is how the pathway usually works:
This is why a clear written report — and, where helpful, a second opinion on the pathology — matters so much before treatment starts. Ask a CION neuro-oncologist to walk you through your markers.
Under the 2021 WHO CNS classification, molecular markers can override how the cells look under the microscope. For example, certain genetic features can make a tumour that appears lower-grade behave — and be graded — as Grade 4. This is why testing for markers such as IDH, MGMT and 1p/19q is now considered a core part of confirming a brain tumour grade, alongside traditional microscopy.
There is one situation where the word "stage" does apply. If a cancer that began somewhere else — such as the lung, breast, kidney or skin (melanoma) — spreads to the brain, those brain lesions are called secondary brain tumours (brain metastases).
A brain metastasis is not given its own WHO grade. Instead, it usually means the original cancer is now Stage 4 (metastatic) disease, because it has reached a distant organ. The stage belongs to the primary cancer; the brain lesions are described by their number, size and location. Treatment for the brain lesions — radiation therapy such as focused radiosurgery, systemic drug therapy, and surgery coordinated with accredited neurosurgical partners — is planned alongside treatment for the primary cancer.
If your primary cancer team has found spread to the brain, CION's neuro-oncology and primary-cancer teams coordinate the plan together, so nothing falls between the cracks.
A brain tumour grade shapes every decision that follows, so it is reasonable — and often wise — to confirm it. Consider a second opinion if:
We walk this journey with you — with transparent costs and decisions made for healing, not billing. Book a free consultation or call 18002028726.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable if molecular testing (IDH, MGMT, 1p/19q) has not yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Not in the usual way. Most cancers use a TNM stage (Stage 1 to Stage 4) based on how far the cancer has spread through the body. Primary brain tumours almost never spread outside the brain and spinal cord, so the TNM system does not fit them. Instead, doctors use a WHO grade (Grade 1 to Grade 4), which describes how abnormal and fast-growing the tumour cells look under a microscope. So when someone asks "what stage is my brain tumour?", the more accurate question is usually "what grade is it?" You can read more on our WHO brain tumour grades explained page.
A stage answers "how far has the cancer spread?" — it maps the size of the primary tumour, whether nearby lymph nodes are involved, and whether it has reached distant organs. A grade answers "how aggressive do the tumour cells look?" — it is decided by a pathologist examining the tissue and, increasingly, its molecular markers. Because brain tumours stay local, grade is the number that guides treatment urgency and prognosis. A high-grade tumour needs faster, more intensive treatment than a low-grade one, regardless of any "stage".
The World Health Organization (WHO) grades brain tumours from Grade 1 to Grade 4. Grade 1 tumours grow very slowly and are often curable with surgery alone. Grade 2 tumours grow slowly but can progress over years. Grade 3 tumours are moderately aggressive and usually need surgery, radiation and chemotherapy. Grade 4 tumours — such as glioblastoma — are the most aggressive and fast-growing. Since the 2021 WHO update, the grade is decided using both how the cells look and molecular markers such as IDH mutation, so two tumours that look similar can now be graded differently.
Staging systems were built to track cancers that spread — from the original organ, to lymph nodes, to distant sites. Primary brain tumours behave differently: they grow and invade within the brain but rarely travel to other organs, so there is nothing distant to "stage". What matters most for the brain is how quickly the tumour is likely to grow and how much it invades nearby tissue — and that is exactly what the WHO grade captures. This is why neuro-oncology guidelines from the NCCN and EANO use grade, not stage, to plan treatment.
A brain metastasis is not given its own grade — it takes its identity from the original cancer. If lung, breast or kidney cancer spreads to the brain, that is generally counted as Stage 4 (metastatic) disease of the original cancer, because the cancer has now reached a distant organ. In these cases the "stage" belongs to the primary cancer, while the brain lesions are described by number, size and location. If your primary cancer has spread to the brain, our teams for lung cancer, breast cancer and kidney cancer coordinate directly with neuro-oncology.
No. Grade describes how the cells behave, not a fixed sentence. Many Grade 1 and Grade 2 tumours are controlled for many years, and some are cured with surgery. Higher-grade tumours are more serious, but treatment — surgery coordinated with accredited neurosurgical partners, radiation therapy, and systemic (drug) therapy — can meaningfully extend life and control symptoms. Outcomes vary widely by tumour type, molecular markers, age and general health, so prognosis is always individual. At CION, every case is reviewed by a tumour board so your plan reflects your exact grade and markers, not a generic average.
The grade is confirmed on tissue. After an MRI suggests a tumour, a sample is obtained through surgery or a stereotactic biopsy — coordinated with accredited neurosurgical partners. A pathologist examines how abnormal the cells look and how quickly they appear to be dividing. Modern grading also uses molecular testing — markers such as IDH mutation, MGMT methylation and 1p/19q co-deletion — because these change both the grade and the best treatment. This is why a written report and, where helpful, a second opinion on the pathology matter so much before treatment begins.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.